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OBJECTIVES: To assess the relative effects and costs of Oralair® versus Grazax®,
ALK Depot SQ® (alongside symptomatic medication) and symptomatic treatment
alone for grass pollen allergic rhinitis; based on a systematic literature review,
meta-analysis and cost-effectiveness analysis. METHODS: The costs and effects of
three year treatment were assessed for a period of 9 years using a Markov model.
Efficacy was estimated using an indirect comparison of available clinical trials.
Estimates for immunotherapy discontinuation, occurrence of asthma, health state
utilities, drug acquisition costs, resource use and other medical costs were derived
from published sources. The analysis was conducted from the German payer’s
perspective, including Statutory Health Insurance (SHI) payments and co-pay-
ments by insurants. Effects were reported as quality adjusted life years (QALYs)
and symptom-free days (SFDs). The uncertainty around the incremental model
outcomes was tested by means of extensive deterministic univariate and probabi-
listic sensitivity analyses; various scenario analyses were also conducted.
RESULTS: In the base case analysis the model predicted a cost-utility ratio of Or-
alair® versus symptomatic treatment of €14,728 per QALY: incremental costs were
€1,356 (95%CI: €1,230;€1,484) and incremental QALYs 0.092 (95%CI: 0.052;0.140). Or-
alair® was the dominant strategy compared to Grazax® and ALK Depot SQ®, with
estimated incremental costs of -€1,142 (95%CI: -€1,255;-€1,038) and -€ 54 (95%CI:
-€188;€85) and incremental QALYs of 0.015 (95%CI: -0.025;0.056) and 0.027 (95%CI:
-0.022;0.075), respectively. At a willingness-to-pay threshold of €20,000, the proba-
bility of Oralair® being the most cost-effective treatment was predicted to be 79%.
The univariate sensitivity analyses show that the results were especially sensitive
to changes in transition probabilities of immunotherapy discontinuation and effi-
cacy estimates. Calculations on SFDs showed a comparable cost-effectiveness
trend. CONCLUSIONS: The analysis suggests Oralair® to be cost-effective com-
pared to Grazax®, ALK Depot SQ® and symptomatic treatment. The robustness of
these statements has been confirmed in extensive sensitivity analyses.
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OBJECTIVES: To conduct comparative pharmacoeconomic analysis of Methylpred-
nisolone aceponate (MA) and Betamethasone valerate (BV, brand name drug) for
treatment of atopic dermatitis and eczema in adults. METHODS: Review of the
published studies has been conducted to evaluate the comparative efficacy and
safety of studied drugs. The cost-minimization analysis was used further. The
pharmaceutical costs were calculated on the basis of average wholesale prices
(according to RMBC/IMS database for the 3d quarter of 2010) and average retail
prices in Moscow drugstores on 15.12.2010. The dosing regimen for both drugs was
1 g per 30 cm2 for 10 days, MA once a day, BV twice daily. RESULTS: A review of
clinical efficacy and safety of topical corticosteroids studies has not revealed sig-
nificant differences between MA and BV, though the experts consider MA to have
more favorable therapeutic index (combination of high anti-inflammatory activity
with reliable safety profile) compared to BV. With the retail price the costs of atopic
dermatitis and eczema treatment were almost equal for MA and brand name drug
of BV: MA cream - 257,85 19,83 RUB (9,15 0,70 $), BV cream - 265,61 33,34 RUB
(9,43 1,18 $), MA ointment- 257,85 19,83 RUB (9,15 0,70 $), BV ointment - 265,61
 33,34 RUB (9,43  1,18 $). CONCLUSIONS: Costs of MA and brand name BV for
treating atopic dermatitis and eczema in adults are identical in both retail and
wholesale market segments. Thus MA may be considered as a preferable option
being a medication with the better therapeutic index compared to BV.
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OBJECTIVES: The community-acquired respiratory tract infections (CARTI) are the
most frequent indicators for antibacterial preparations prescription, that requires
significant costs. Traditionally, penicillins and macrolids are used for it. Certain
perspectives of CARTI treatment are connected with the new generation respira-
tory fluoroquinolones use, that have high antibacterial activity in relation to S.
pneumoniae, but are rather expensive, especially in Ukraine. The aim of this work
was comparative evaluation of costs efficiency for patients treatment with com-
munity-acquired pneumonia (CAP) and exacerbations of chronic bronchitis (ECT)
with antibacterial preparations such as fluoroquinolone moxifloxacin versus ma-
crolid clarithromycin for the optimal use of patient’s or state’s financial expenses
grounding. METHODS: cost-minimization and sensitive analysis. RESULTS: The
results of G. Hoffken, H.P. Meyer, K. Sprenger et al.(1999) have been used for phar-
macoeconomic evaluation. In the trial 531 patients took place and it lasted 10 days.
The treatment regimes were: moxifloxacin (200 mg / day); moxifloxacin (400 mg /
day); clarithromycin (500 mg / two times a day). For pharmacoeconomic evaluation
of ECT treatment the results of trial (R. Wilson, R. Kubin, I. Ballin et al., 1999) have
been used: 649 patients took part in trial. The trial lasted 7 days. The treatment
regimes were: moxifloxacin (400 mg / one time a day) for 5 days, clarithromycin (500
mg / two times a day) for 7 days. Efficacy of moxifloxacin and clarithromycin for
CAP and ECT was equal. CONCLUSIONS: The results of “cost-minimization” anal-
ysis are sensitive to prices for drugs changing, and it does not create stable advan-
tages for clarithromycin. In case of maximal price for drugs, it is moxifloxacin that
has advantages.
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OBJECTIVES: Asthma is a common chronic disease affecting approximately 4 mil-
lion or 6.2% of Thais. Most asthmatic patients under the universal health coverage
(UC) scheme are poor, and cannot access to appropriate treatments due to geo-
graphical barriers, and high costs of medications. Severe asthmatic patients not
improved with inhaled corticosteroids (ICS) and long acting beta agonists (LABA)
rarely access to Omalizumab, an anti IgE medication, because of its high costs, and
exclusion from the UC benefit package. This study explores cost-utility analysis in
societal perspective between Omalizumab and standard medical treatments (ICS,
LABA, or oral corticosteroid) for severe asthmatic patients. METHODS: A mathe-
matical model using variables and data from comprehensive literature reviews and
asthma policy model were employed. Data on costs of medication and health ser-
vice use were computed from existing reports of the Ministry of Public Health. The
quality of life of asthma patients was assessed by the Asthma Quality of Life Ques-
tionnaire (AQLQ). RESULTS: Results from the mathematical model indicate that
using Omalizumab compared to other standard medical treatments would achieve
231 quality-adjusted years (QALY) with additional costs of 95 million Baht (approx-
imately US$ 3 million) for 100 severe asthmatic patients. The incremental cost-
effectiveness ratio (ICER) of Omalizumab is approximately 414,503 Baht (US$13,371)
per QALY gained. This ICER exceeds 1 GDP per capita which is the criteria for
including new health interventions into the UC benefit package. CONCLUSIONS:
Omalizumab is not cost-effective for severe asthma patients in Thailand. It is rec-
ommended that improving access to ICS and LABA and maintenance systemic
steroid should be the priority of medial care for asthma patients in Thailand, prior
to including Omalizumab into the UC benefit package. Omalizumab will be consid-
ered to be cost-effective if its cost decreases significantly and used for severe ast-
matic patients only.
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OBJECTIVES: Despite availability of current treatments, patients with chronic ob-
structive pulmonary disease (COPD), associated with chronic bronchitis, often ex-
perience life-threatening and costly exacerbations. The aim of this analysis was to
assess the long-term costs and outcomes associated with different treatment op-
tions for the management of severe COPD in the UK. METHODS: A Markov cohort
model was constructed to simulate decline from severe to very severe COPD (as
defined by the NICE/GOLD guidelines), treatment regimen changes, and death.
Community- and hospital-treated exacerbations were modelled as events within
each health-state. A fully incremental cost-effectiveness analysis was conducted
for LABA, LAMA, PDE-4 inhibitors, and ICS in various combinations. Transition
probabilities for COPD progression were derived from published epidemiological
sources. Relative rate ratios of exacerbations were taken from a recently published
mixed treatment comparison. Direct costs were sourced from UK data, and health
state utilities and exacerbation disutilities from the published literature. Analyses
were conducted from the UK NHS perspective, based on a 30-year time horizon,
with costs and outcomes discounted at 3.5% p.a. One-way and probabilistic sensi-
tivity analyses were conducted. RESULTS: The cost-efficiency frontier suggests
LAMA as the most effective monotherapy (£22,370, 5.421 QALYs). If patients con-
tinue to exacerbate, LAMALABA/ICS is a cost-effective second line option (£22,816,
5.484 QALYs, ICER £7,045/QALY), followed by LAMALABA/ICSroflumilast (£23,230,
5.509 QALYs, ICER £16,566/QALY). For patients who are intolerant to (or decline) ICS,
the addition of roflumilast to LAMALABA is a cost-effective treatment option (ICER
£13,764/QALY). The results were consistent under a variety of assumptions.
CONCLUSIONS: For severe COPD patients who continue to exacerbate, despite
current standard of care, the addition of roflumilast to the treatment regimen is
cost-effective in UK clinical practice. The addition of roflumilast in this manner is
consistent with the step-wise treatment paradigm recommended in NICE guide-
lines.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a progressive (and
non-completely reversible) inflammatory lung disease. Disease progression is as-
sociated with increasing morbidity, mortality and economic burden. As compared
to usual care, tiotropium treatment and pulmonary rehabilitation programs have
been reported to improve the health of COPD patients in terms of exacerbations,
quality of life, and mortality. However, to date, the cost-effectiveness/utility of
these therapies in French settings have not been reported. We estimated the cost-
utility/effectiveness of these therapies in a patient population recruited from
French general practitioners and lung specialists. METHODS: A Markov model of
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the disease was developed and the study adopted society’s perspective while the
horizon time considered was patient’s remaining lifespan. Cohorts of COPD pa-
tients treated with Tiotropium or cohorts of patients undergoing pulmonary reha-
bilitation programs were simulated (Monte-Carlo simulations in TreeAge software)
and compared to identical cohorts of patients subjected to usual care. Life expec-
tancies, quality adjusted life-years (QALY), disease-related costs, and incremental
cost-utility ratios were estimated. RESULTS: At the horizon of a patient’s remain-
ing lifetime (14.29 life years in average, considering a population combining mod-
erate to very severe patients), tiotropium would result in 0.12 life years and 0.58
QALY gained (mean estimates), induce an additional cost of 5380 €/patient in the
disease-related costs, with a corresponding incremental cost-utility ratio of 8853
€/QALY. For pulmonary rehabilitation programs, these estimates were 0 life years,
0.31 QALY, 2,969 €, and 12,000 €/QALY, respectively. Results were mostly sensitive
to the utility changes associated with exacerbations. CONCLUSIONS: Tiotropium
treatment and pulmonary rehabilitation programs were estimated as worth inter-
ventions in the studied population, below the usual threshold used for declaring
procedures as cost effective. Nevertheless, the modest gains in health issued from
the study emphasize the need of research for developing more effective COPD-
related therapies.
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OBJECTIVES: To assess costs, utilities and cost-utility of fixed combination salme-
terol/fluticasone (SAL/FP maintenance treatment) versus non-fixed combination
budesonide  formoterol in one pack (BUDFORM maintenance treatment) in the
management of patients with bronchial asthma by means of an OPTIMA model.
METHODS: In this analysis we used the following data: drug prices (from List of
Maximum Permissible Manufacturer Prices for Vital and Essential Drugs) and drug
dosage proportion (from MRC Pharmexpert, 4Q 2010); number of inhalations per
day (from instructions); QOL and number of health care resources for controlled
and uncontrolled asthma (from published sources); resource unit costs (from 2010
health care insurance program). Work-off day costs included tax deficiency, GDP
underproduction and sick pay. Frequency of controlled asthma was obtained from
ARROW study (Ogorodova et al., 2009) for SAL/FP (73%) and from FACET trial
(O’Byrne et al. 2008) for BUDFORM (62%). Conceptual formula of analysis was: cost
of drugs% controlled * cost of controlled% uncontrolled * cost of uncontrolled.
One-way sensitivity analysis was conducted to assess the robustness of the results.
RESULTS: Average monthly costs of drugs were 1,677 RUR/€42 and 2,023 RUR/€51
for SAL/FP and BUDFORM respectively. Medical costs and QOL measures were 378
RUR/€9 and 0.75 for controlled asthma; 88,295/€2,207 RUR and 0.49 for uncontrolled
asthma. Yearly total costs per patient were higher for BUDFORM than for SAL/FP
(58,057/€1,451 RUR vs. 44,244 RUR/€1,106). Compared to BUDFORM, SAL/FP was
associated to an expected increase of QALYs per patient (0.68 QALYs vs. 0.65
QALYs). The cost-utility analysis showed that SAL/FP was dominant (less costly
and more effective in terms of QALYs gained). Results were sensitive to all the
parameters varied in the sensitivity analysis, especially health care costs.
CONCLUSIONS: Treatment of patients with bronchial asthma with SAL/FP is a
dominant strategy in comparison with non-fixed combination BUDFORM in one
pack.
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OBJECTIVES: Smoking is the leading cause of preventable death in El Salvador
(50%) and results in many serious comorbidities, including lung cancer, coronary
heart disease, stroke and chronic respiratory disease. The aim of this study was to
evaluate the cost-utility of varenicline compared to other existing strategies for
smoking cessation within a 5-year time horizon in El Salvador using the healthcare
payer’s perspective. METHODS: The Benefits of Smoking Cessation on Outcomes
(BENESCO) simulation model was used for an adult cohort (n4,537,803). Diseases
included were: stroke, lung cancer, coronary heart disease and chronic obstructive
pulmonary disease. Smoking cessation therapies compared were: varenicline (0.5 –
2 mg/day), bupropion (300 mg/day), nicotine replacement treatment (NRT) (5-10
mg/day) and unaided cessation. Effectiveness measure was: quality-adjusted life
year gained (QALY’s), which was obtained from published literature. Resource use
and costs data were obtained from El Salvador’s Ministry of Health and Social
Security official databases (2010). The model used a 3% discount rate for costs
(expressed in 2010 US dollars) and QALYs. Probabilistic sensitivity analyses (PSA)
were conducted and acceptability curves were constructed. RESULTS: Varenicline
reduced smoking related morbidity, mortality and healthcare costs. After 5 years,
Varenicline gained 306,158 QALYs, which represents 73, 94 and 178 more QALYs
than bupropion, NRT and unaided cessation, respectively. Overall costs showed
varenicline as the least expensive option against bupropion (US$328,558), NRT
(US$412,730) and unaided cessation (US$777,124). Cost-effectiveness analyses
showed that varenicline was the dominant strategy. Acceptability curves showed
that varenicline would be cost-effective within 3 GDP per capita threshold. PSA
results support the robustness of the findings. CONCLUSIONS: Smoking cessation
therapy with varenicline is cost-saving in El Salvador. These results could help to
reduce the tobacco related disease burden and align cost-containment policies.
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OBJECTIVES: To estimate annual medical and productivity costs attributable to
obesity in adult patients with asthma in the US. METHODS: This study used the
2003-2008 Medical Expenditure Panel Survey. Asthma patients(18-64 years) were
identified using ICD-9-CM code 493, clinical classification code-128, or physician
diagnosis. Patients were classified as normal(BMI:18.5-25 kg/m2), overweight-
(BMI:25-30 kg/m2) or obese(BMI:30 kg/m2). Medical costs were estimated using
a generalized linear model(GLM) with a log link function and gamma distribution.
Costs associated with productivity loss were calculated based on missed working
days due to illness and average hourly wage using a two part model. In the first
part, logistic regression was used to estimate the probability of having missed
working days due to illness. In the second part, among patients with missed work-
ing days, GLM was used with the estimated probability from first part of model to
estimate the cost associated with productivity loss. The costs attributable to obe-
sity were estimated by differences between the observed and estimated cost in
obese patients, using a distribution of covariates obtained from normal patients.
All costs were converted to 2010 US dollars using price indices. RESULTS: A total of
8775 adults were identified with asthma. The average treatment cost and lost pro-
ductivity costs of normal patients were $3154(95%CI:$2689-$3620) and $327(95%CI:
$279-$375), and those of obese patients were $5720(95%CI:$5314-$6129) and
$699(95%CI:$608-$790), respectively. Obese patients had 38% higher medical cost
and 53% higher lost productivity costs after adjusting for other study variable.Ad-
ditional medical costs attributable to obesity were calculated at $1087 (95%CI:$687-
$1487) and lost productivity costs attributable to obesity were $279(95%CI:$191-$368).
CONCLUSIONS: The economic burden of asthma among US adults is substantial
which is only further amplified by the presence of obesity. This study highlights the
importance of obesity control to reduce the cost of treating asthma patients and
enhance productivity.
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OBJECTIVES: The objective is to describe the healthcare resource utilization and
cost patterns associated with severe uncontrolled allergic asthma, based on data
from Dutch patients collected in the EXPERIENCE study. METHODS: EXPERIENCE
was a prospective, open-label, observational, multicenter, multicountry study in
patients with severe persistent allergic asthma treated with omalizumab. The
Global Evaluation of Treatment Effectiveness (GETE) was used to evaluate patient
response. Healthcare resource use and number of exacerbations were captured for
one year prior to the start of the study for all patients and continued for 104 weeks
until end of the study. Hospitalizations, specialist visits and medications were
included in this analysis for year before study and first year of study. Unit cost
prices taken from 2010. RESULTS: A total of 154 subjects were included in ITT
population. There were 2.5 clinically significant (CS) exacerbations/patient year
prior compared to 0.90 CS exacerbations/patient for year of study on omalizumab.
The total number of CS severe (CSS) exacerbation was 0.95 CCS exacerbations/
patient for year prior and 0.26 CSS exacerbations/patient for year of study. The
results indicate that patients in this study have an average cost of €4257/patient in
the year prior to the study and €2583/patient cost during the study year, excluding
omalizumab costs. The biggest cost drivers are hospitalization, work days lost and
other asthma medications. The total omalizumab costs were €12,652/patient plus
€1,171/patient for administration cost. CONCLUSIONS: This study reflects real life
clinical practice and associated costs for omalizumab treatment of severe allergic
asthma patients. It indicates a reduction in CS and CSS exacerbation rates of 64%
and 73%, respectively associated with a 40% reduction in treatment costs when
using omalizumab. Keeping in mind the study limitations associated with the
observational setting, it provides estimated costs for patients with severe uncon-
trolled allergic asthma based on ‘real-world’ Dutch practice patterns.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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